CB Pharma Acquisition Corp. Announces Exercise of Portion

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
CB Pharma Acquisition Corp. Announces Exercise of Portion of Over-Allotment Option in Conjunction With Its IPO

BURLINGTON, Mass., Dec. 29, 2014 (GLOBE NEWSWIRE) -- CB Pharma Acquisition Corp. (Nasdaq: CNLMU ) ("CB Pharma" or the "Company"), a Cayman Islands exempted company formed as a blank check company for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities, announced in connection with the Company's public offering of 4,000,000 units, it has completed the sale of an additional 200,000 units pursuant to the 45-day over-allotment option granted to the underwriters in its public offering to purchase up to an additional 600,000 units. The issuance of the additional 200,000 units closed on December 24, 2014. The Company also consummated a simultaneous private placement of an additional 1,000 private placement units to EarlyBirdCapital, Inc.

The 4,200,000 units sold in the public offering, including the 200,000 units sold pursuant to the over-allotment option, were sold at an offering price of $10.00 per unit, generating total gross proceeds of $42,000,000. Of the gross proceeds of the public offering and simultaneous private placements, $42,845,000 (or approximately $10.20 per share sold in the public offering) was placed in trust.

EarlyBirdCapital, Inc. acted as the sole book-running manager for the offering. Aegis Capital Corp. and I-Bankers Securities acted as co-managers.

The initial public offering was made only by means of a prospectus. Copies of the prospectus may be obtained by contacting EarlyBirdCapital, Inc., Attention: Prospectus Department, 366 Madison Avenue, 8th Floor, New York, New York 10017, Attn: Aimee Bloch, (212) 661-0200.

A registration statement relating to CB Pharma's securities had been filed with, and declared effective by, the Securities and Exchange Commission on December 12, 2014. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About CB Pharma Acquisition Corp.

CB Pharma is a Cayman Islands exempted company formed for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. The Company's efforts to identify target businesses will not be limited to a particular industry or geographic region, though it intends to initially focus its search on businesses in North America, Europe, South America, and/or Asia operating in the specialty pharma and generic drug industries. This could include acquiring the rights to a drug approved by the United States Food and Drug Administration or other "branded" pharmaceutical products or a company holding such rights.

Forward-Looking Statements

This press release includes "forward-looking statements" that are not historical facts, and involve risks and uncertainties that could cause actual results to differ materially from those expected and projected. Words such as "expects", "believes", "anticipates", "intends", "estimates", "seeks" and variations and similar words and expressions are intended to identify such forward-looking statements. Such forward-looking statements relate to future events or future performance, but reflect CB Pharma management's current beliefs, based on information currently available. A number of factors could cause actual events, performance or results to differ materially from the events, performance and results discussed in the forward-looking statements. For information identifying important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the Risk Factors section of CB Pharma's prospectus for its offering filed with the Securities and Exchange Commission. Except as expressly required by applicable securities law, CB Pharma disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events, or otherwise.

CB Pharma Acquisition Corp. Lindsay A. Rosenwald, M.D. Co-Chairman of the Board and Chief Executive Officer 781-652-4500

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sovereign Crown Vault's Auction Draws Numismatic Collectors

Updated Category News Views 61

A Legendary Auction with Three Generations of Passion Coins, eh? They might just be small metallic disks to the untrained eye, but these suckers tell stories that stretch beyond any bank ledger. Sovereign Crown Vault LLC knows this, and they’re gearing up for quite the show on November 22, 2026. Their Holiday Season Kickoff Spectacular is about to lure in collectors...

Continue Reading
ZTE Reinvents Energy for AI Data Centers

Updated Category News Views 236

The Great Race: Power and AI in Sync Here we are, neck-deep in the AI era, where the demand for raw computing power just won’t quit. With every data-hungry application and supercharged algorithm, companies are scrambling to keep up. But there’s a nasty little dragon in this fairy tale—energy efficiency. ZTE isn’t just acknowledging this beast; they’re ready to...

Continue Reading
Webull Faces FINRA Fine and Legal Battle Ahead

Updated Category News Views 187

Webull's Compliance Headache Webull’s been knocked around again. This time, the Financial Industry Regulatory Authority (FINRA) slapped it with a hefty $4.2 million fine. Talk about a hit to the wallet! It all boils down to them failing to roll out some basic anti-money laundering (AML) and other crucial compliance programs. This is no small oversight, and it's got...

Continue Reading
Older Adults Embrace Cosmetic Dentistry for Confidence

Updated Category News Views 114

Why the Shift to Cosmetic Dentistry Later in Life? Aging doesn't just wrinkle your skin; it affects your smile too. Dr. Joseph T. Sumrall and Dr. Gran Sumrall, the dental gurus of Warner Robins, Georgia, are laying out why more adults are jumping on the cosmetic dentistry bandwagon as they age. Spoiler: It ain't about getting a movie-star grin but something much deeper....

Continue Reading
Pinot's Palette Expands with New La Quinta Studio

Updated Category News Views 79

Canvas and Cabernet in Coachella Valley Grab your brushes and wine glasses; Pinot's Palette is branching out to La Quinta. As of November 27, locals and visitors alike can find their artistic flair at 47120 Dune Palms Road. This move isn’t just another business expansion—it's about blending community spirit with creativity, backed by the experienced entrepreneurs...

Continue Reading
Avoid FOGs: Illinois Water's Holiday PSA

Updated Category News Views 102

Don't Ignore the Kitchen Sink This Holiday You ever poured something down the drain and just prayed it wouldn't come back to bite you later? Well, Illinois American Water is throwing up a big, red flag about doing exactly that during the holidays. When we're all busy passing the gravy boat and diving into festive feasts, it's easy to forget the after-party might just turn...

Continue Reading
TOYO Slips on Earnings Amid Strategic Expansion

Updated Category News Views 206

TOYO's Solar Journey: Ups and Downs If there's one thing riding high on volatility these days, it's solar energy. TOYO Co., Ltd. (Nasdaq: TOYO) spilled the beans on Q3 2026, and oh boy, it's a mixed bag. Revenue Jumps, Yet Profitability Takes a Hit Let's cut to the chase: the third quarter served up a 4.8% dip in revenue year-over-year, landing at $129 million, though it...

Continue Reading
LinkedIn Shines: Brands Face Social Media Slump

Updated Category News Views 77

LinkedIn: The Unsung Hero in Social Platforms In a world where social media seems to be as unpredictable as the stock market, LinkedIn is surprisingly holding the line. According to Vista Social's 2027 report, LinkedIn proudly boasts the highest median engagement rate among brand pages at 5.8%. Now, in the wild west of social media, where reach is getting tougher to snag,...

Continue Reading
Tackling the Industrialized Beast of Insurance Fraud

Updated Category News Views 39

Stepping Up the Fraud Fight This year's emerging fraud trends are taking the term 'organized crime' to new heights, and it's painting a bullseye on the insurance industry. The National Insurance Crime Bureau (NICB) just laid out how fraud isn't just a series of isolated scams anymore—it's an industrial-scale racket. As they spotlight during International Fraud Awareness...

Continue Reading
PolyBio Convergence Summit Tackles Aging, Chronic Illness

Updated Category News Views 94

Kicking Off The Convergence: Pathogens in Focus Here's a gathering that's set to challenge how we think about lingering illnesses and aging. PolyBio Research Foundation is bringing a powerhouse of brains to the table with their inaugural Convergence Summit. It's more than just science talk; it's a chance to push boundaries in understanding how pathogens stick around and...

Continue Reading

Top 5 Most Recently Viewed Articles

Ocean Power Technologies Enhances Market Reach with New Partnership

Updated Category News Views 124

Expanding Horizons in Latin America Ocean Power Technologies, Inc. (NYSE American: OPTT), a pioneer in low-carbon marine power solutions, has taken a significant step in expanding its operational footprint by signing a reseller agreement in Latin America. This significant partnership primarily targets the offshore and maritime sectors in Mexico. A New Partnership for...

Continue Reading
Aktsiaselts Infortar's Strategic Move in the Polish Energy Sector

Updated Category News Views 121

Aktsiaselts Infortar Expands Into Poland's Energy Market Aktsiaselts Infortar, through its wholly owned subsidiary AS Eesti Gaas, has taken a significant step in its growth strategy by acquiring 100% of EWE Polska sp. z o.o., an important player in the Polish energy sector. This strategic acquisition enables Infortar to broaden its operational footprint beyond the...

Continue Reading
Exciting Insights Await at Can-Fite's Live Investor Webinar

Updated Category News Views 151

Join Can-Fite BioPharma's Informative Live Investor Webinar Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) is thrilled to announce an exclusive live investor webinar aimed at sharing vital insights into their innovative drug pipeline. This engaging session will take place on a Tuesday afternoon, providing an excellent opportunity for investors and stakeholders...

Continue Reading
Ajinomoto Co. Partners with LabCentral to Boost Biotech Innovation

Updated Category News Views 365

Ajinomoto Co., Inc. Enhances Biotech Innovation Ajinomoto Co., Inc., a prominent player in biotechnology and food innovation, recently unveiled its full-scale support for LabCentral, a distinguished platform for startups in the biosciences sector. This initiative reaffirms the Ajinomoto Group's dedication to innovation and collaborative growth within an ever-evolving...

Continue Reading
ATI Physical Therapy's Strategic Shift to Private Ownership

Updated Category News Views 610

ATI Physical Therapy Shifts to Private Ownership ATI Physical Therapy, Inc. (OTC: ATIP), known for its outstanding outpatient physical therapy and rehabilitation services, has made a significant transition. In a recent announcement, the company disclosed its evolution from public to private ownership, led by a consortium of existing shareholders including Knighthead...

Continue Reading